Deal Flow
Letter · prints on one page
Transaction tear sheetData as of Nov 7, 2026
M&A · Healthcare · Electromedical & Electrotherapeutic Apparatus

KKR & Co. Inc. to acquire Integer Holdings Corp

Announced Aug 3, 2026 · Terminated Sep 30, 2026

Deal value$5.70BEV $5.70B
Premium51.8%To unaffected price
EV / Adj. EBITDA15.1x3.1x EV / Revenue
ConsiderationAll cash$127.00 per share

Transaction

Acquirer
KKR & Co. Inc. (KKR)
Target
Integer Holdings Corp (ITGR)
Buyer type
Private equity
Offer price per share
$127.00
Enterprise value
$5.70B
Status
Terminated Sep 30, 2026

Deal protections

Break fee (target pays)
$154M · 2.7%
Reverse fee (buyer pays)
$307M · 5.4%
Go-shop
No-shop
Financing
Committed · Goldman Sachs

Advisors

To the acquirer
Centerview, Barclays, Citigroup, Raymond James
To the target
Goldman Sachs

Sector context · Healthcare

Comparable deals
109 in the prior 24 months
Premium
51.8% vs. 46.0% sector median
EV / Adj. EBITDA
15.1x vs. 10.9x sector median
Break fee
2.7% vs. 3.5% sector median

Timeline

  1. AnnouncedAug 3, 2026
  2. Proxy filedSep 3, 2026
  3. Definitive proxySep 14, 2026
  4. Shareholder vote—
  5. TerminatedSep 30, 2026

Valuation · fairness opinions

Discounted cash flow$98.93$140.68
Discounted cash flow$88.57$127.71
Future share price$86.00$106.00
Premiums paid$97.00$120.00
Offer $127.00

Implied value per Integer Holdings Corp share by analysis, from Goldman Sachs · DCF discount rate 9%–10%.

Sources
  • 8-K (EX-99.1) · Aug 3, 2026
  • 8-K (EX-99.1) · Aug 3, 2026
  • DEFA14A (EX-99.1) · Aug 3, 2026
  • DEFA14A · Aug 3, 2026
  • 8-K · Aug 4, 2026
  • 8-K (EX-99.1) · Sep 30, 2026

Adj. EBITDA is operating income + D&A + impairment, restructuring, deal costs and stock compensation, less any large gain on a sale, last twelve months, from the target's filings. Calculated by Castle, so it can differ from a bank's adjusted figure.

Prepared with Castle from public SEC EDGAR filings. Figures are extracted automatically; verify against the source documents. Not investment advice.